Iovance Stock Plunges as FDA Puts Hold on Lung Cancer Study After Patient Death

Iovance Biotherapeutics stock was tumbling Wednesday after the Food and Drug Administration placed a clinical hold on a cancer treatment study following the death of a study patient.

Continue reading this article with a Barron’s subscription.

View Options

Source link